-

11:09:51 AM

JAGX Stock News

JAGX - Jaguar Health Inc

03/15/23 8:30 AM

Nasdaq : JAGX

low float

Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities

RHEA-AI

very positive

03/13/23 8:30 AM

Nasdaq : JAGX

low float

Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug

Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company is developing an artificial

RHEA-AI

neutral

03/02/23 8:30 AM

Nasdaq : JAGX

conferenceslow float

Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases

Presentation will cover Jaguar and Napo Therapeutics' focus on development and commercialization of crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) Crofelemer has received orphan drug designation from the FDA and the European Medicines Agency for both SBS and a

RHEA-AI

neutral

02/28/23 8:30 AM

Nasdaq : JAGX

low float

FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US

Jaguar Health (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation

RHEA-AI

very positive

02/23/23 8:30 AM

Nasdaq : JAGX

fda approvallow float

Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office

RHEA-AI

neutral

02/21/23 8:30 AM

Nasdaq : JAGX

clinical triallow float

Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea

RHEA-AI

very positive

02/09/23 8:30 AM

Nasdaq : JAGX

low float

Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.

This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million Jaguar currently owns approximately 73.5% of Napo Therapeutics Napo Therapeutics' mission is to provide access to

RHEA-AI

neutral

02/08/23 8:30 AM

Nasdaq : JAGX

low float

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on February 7, 2023 the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that Jaguar has

RHEA-AI

neutral

02/01/23 9:45 AM

Nasdaq : JAGX

low float

Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and SynWorld Technologies Corporation (SynWorld) today

RHEA-AI

neutral

02/01/23 8:30 AM

Nasdaq : JAGX

low float

Jaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short Selling

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has entered into a service agreement with Shareholder Intelligence Services, LLC ( ShareIntel), a leading compliance driven SAAS platform, to track market

RHEA-AI

negative

1 2 3 4 5 6 7 8 9 10 Next

JAGX Data

IndustryPharmaceutical Preparation Manufacturing
Websitejaguar.health
CeoLisa Conte
Security nameJaguar Health Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees52
Tags
- Health Technology
- Pharmaceuticals: Generic
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address200 Pine Street Suite 400
StateCalifornia
CitySan Francisco
Zip94104
CountryUS
Phone14153718300

About Jaguar Health Inc

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Its Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.